Kinnate Biopharma Inc.
KNTEDelisted Apr 3, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001797768
Kinnate Biopharma Inc. was delisted on Apr 3, 2024; its insiders filed their last Form 4 on Apr 5, 2024; 56 institutions reported holding it in 13F filings for Q1 2024, worth $92.2M in total; Viking Global Investors was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 56
- Q1 2024, −6 vs. previous quarter
- 13F value
- $92.2M
- Reported value at the end of Q1 2024
- Superinvestors holding
- 1
- At the end of Q1 2024
Superinvestors holding KNTE, Q1 2024
1 superinvestor reports holding Kinnate Biopharma Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
<0.1%
Kinnate Biopharma Inc.'s share of the portfolio
- Shares
- 1,820,462
- Value
- $4.84M
Latest insider trades
Open-market purchases and sales by Kinnate Biopharma Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 10, 2023 (view filing)5:42 PM ET | May 8 | 2 days | Foresite Capital Fund IV, L.P. and 5 others10% Owner | PPurchase | +1.78M | $2.80 | +$4.98M | New position520.7K after | 2 lotsDuplicate filing |
| May 10, 2023 (view filing) | May 8 | 2 days | Tananbaum James B.Director, 10% Owner | PPurchase | +1.78M | $2.80 | +$4.98M | New position520.7K after | 2 lots |
| May 8, 2023 (view filing)5:22 PM ET | May 4-5 | 4 days | OrbiMed Advisors LLC and 6 othersDirector, 10% Owner | PPurchase | +1.46M | $2.80 | +$4.09M | New position1.37M after | 5 lotsDuplicate filing |
| May 8, 2023 (view filing) | May 4-5 | 4 days | Gordon Carl LDirector, 10% Owner | PPurchase | +1.46M | $2.80 | +$4.09M | New position1.37M after | 5 lots |
| May 2, 2023 (view filing)9:34 PM ET | Apr 28-May 2 | 4 days | OrbiMed Advisors LLC and 6 othersDirector, 10% Owner | PPurchase | +1.41M | $2.61 | +$3.67M | New position794.4K after | 9 lotsDuplicate filing |
| May 2, 2023 (view filing) | Apr 28-May 2 | 4 days | Gordon Carl LDirector, 10% Owner | PPurchase | +1.41M | $2.61 | +$3.67M | New position794.4K after | 9 lots |
| Mar 15, 2022 (view filing) | Mar 11-14 | 4 days | Williams Richard ThomasChief Medical Officer | PPurchase | +40.0K | $8.47 | +$338.9K | +1,714.5%42.3K after | 2 lots |
| Feb 15, 2022 (view filing)9:42 PM ET | Feb 11-15 | 4 days | OrbiMed Advisors LLC and 3 othersDirector | PPurchase | +195.7K | $10.17 | +$1.99M | +5.9%3.51M after | 4 lotsDuplicate filing |
| Feb 15, 2022 (view filing) | Feb 11-15 | 4 days | Gordon Carl LDirector | PPurchase | +195.7K | $10.17 | +$1.99M | +5.9%3.51M after | 4 lots |
Top 10 13F holders, Q1 2024
The largest institutional positions in Kinnate Biopharma Inc. at the end of Q1 2024; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $25.7M | 13.00% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 8,009,729 | $21.3M | 0.42% | 00.0% | Unchanged |
| Foresite Capital Management V, LLC | 3,525,957 | $9.38M | 8.80% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 1,981,106 | $5.27M | 1.36% | −15,900−0.8% | Reduced |
| Viking Global Investors LPSuperinvestorViking Global Investors | 1,820,462 | $4.84M | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,076,789 | $2.86M | 0.00% | +33,879+3.2% | Added |
| Deltec Asset Management LLC | 1,039,800 | $2.77M | 0.55% | +1,039,800 | New |
| Tang Capital Management LLC | 977,626 | $2.60M | 0.27% | −1,624,021−62.4% | Reduced |
| Acadian Asset Management LLC | 964,881 | $2.56M | 0.01% | +134,388+16.2% | Added |
| Renaissance Technologies LLC | 887,740 | $2.36M | 0.00% | +312,761+54.4% | Added |